|
| Clinical Trials: Open Enrollment |
| The following is a listing of all trials currently enrolling brain tumor patients at UCLA. |
|
|
|
|
| What clinical trials are available at UCLA Neuro-Oncology? |
Choosing to participate in a clinical trial is an important, personal decision. It is often helpful to talk to a physician, family members, or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials.
For more information about any of the UCLA Neuro-Oncology Program’s clinical trials listed, please contact Emese Filka, Clinical Trials Coordinator, at (310) 794-3521
|
| Study Agent | IRB ID | Trial:Details | | 5-FC (Flucytosine) | 10-001147 | [Tg 511-09-01] A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511.: | | Avastin (Bevacizumab) Genetech | 10-000760 (09-06-032) | [AVF4535s] Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma. : | | CC-223 | 11-002219 | [CC-223-ST-001] : | | Cediranib | 10-000907 | [ABTC 09-03] A Phase Ib Study of Cediranib in Combination with Cilengitide in Patients with Recurrent Glioblastoma. : | | IMC-3G3 and IMC-1121B | 11-000738 (10-03-077) | [ABTC 09-01] An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC- 3G3 or IMC-1121B in Patients with Recurrent Glioblastoma Multiforme. : | | PLX3397 | 11-002957 | [PLX108-04] A Phase II Study of Orally Administered PLX3397 in Patients with Recurrent Glioblastoma.: | | RO4929097 and Bevacizumab | 11-000467 | [ABTC 10-02] Ph I/II Study of RO4929097 with Bevacizumab in Patients with Recurrent Malignant Glioma.: | | Toca 511 | 10-000484 (09-07-003) | [Tg 511-08-01] A Phase 1 Ascending Dose Trial of the Safety and Toleratbility of Toca 511 in Patients with Recurrent Glioblastoma Multiforme.: | | VELCADE, TMZ, RT | 11-002222 (09-03-084) | [Velcade X05303] Ph II Trial of VELCADE (Bortezomib) in Combination with Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients with Newly-Diagnosed Glioblastoma Multiforme.: | | XL765 and Temozolomide | 10-001735 (08-01-061) | [XL765-002] Ph I Dose-Escalation Study of XL765 in Combination with Temozolomide in Subjects with Malignant Glioma. : | | XL765 and Temozolomide | 10-001735 (08-01-061) | [XL765-002] Ph I Dose-Escalation Study of XL765 in Combination with Temozolomide in Subjects with Malignant Gliomas.: | | XL765 and XL147 | 10-000344 | [XL765-202] An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects with Recurrent Glioblastoma Who are Candidates for Surgical Resection.: |
|
|
|
|
